Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

31 study showed that giving Imfinzi (durvalumab) as adjuvant therapy for stage IB-IIIA non-small cell lung cancer (NSCLC) was no better than placebo at extending disease-free survival (DFS).

The trial is targeting patients with Stage II, IIIA or IIIB (N2 ... overall survival rates for patients with non-small cell ...

received a positive recommendation from NICE for NHS use as an adjuvant treatment option after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC ...

It's never too late to stop smoking. About 90% of lung cancers are attributable to smoking, and smokers have a 20-fold higher lifetime risk for developing lung cancer than do nonsmokers.

Lung cancer is the leading cause of cancer mortality worldwide, and 80% of lung cancers are non-small cell lung cancers (NSCLCs) (Jemal et al, 2009). Despite improvements in early diagnosis made ...

In 2013, it was designated a National Clinical Research Centre for Cancer by China’s Ministry ... therapy to chemotherapy for stage IIIA non-small cell lung cancer (NSCLC) patients with ...

1,3 Tagrisso (osimertinib) received a positive recommendation from NICE for NHS use as an adjuvant treatment option after complete tumour resection in adult patients with stage IB-IIIA non-small cell ...

Researchers found that, in patients with stage III NSCLC, treatment with cCRT and an ICI was safe, but treatment with cCRT and 2 ICIs led to “excessive mortality.” ...

Tagrisso (osimertinib) is recommended as an adjuvant treatment after complete tumour resection in adults with stage IB-IIIA non-small cell lung cancer (NSCLC) with specific genetic mutations. This ...